Các phân nhóm khác nhau của tế bào lympho xâm nhập khối u có mối tương quan với sự tiến triển của NPC theo những cách khác nhau

Molecular Cancer - 2010
Yi Lan Zhang1, Jiang Li1, Hao Yuan Mo2, Fang Qiu2, Limin Zheng1, Chao Nan Qian1, Yi Xin Zeng3
1State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road east, Guangzhou, 510060, PR China
2Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, PR China
3Department of Experimental Research, Sun Yat-sen University Cancer Center, 651 Dongfeng Road east, Guangzhou, 510060, PR China

Tóm tắt

Tóm tắt Nền tảng Sự gia tăng các bằng chứng cho thấy tế bào lympho xâm nhập khối u (TIL) có tương quan với tiên lượng của bệnh nhân ung thư. Nghiên cứu này tập trung vào mối liên hệ giữa mật độ của tế bào lympho T cytotoxic xâm nhập khối u (CTL), CTL hoạt hóa, tế bào lympho T điều hòa (Treg) và tế bào lympho Th17 với tiên lượng cùng các đặc điểm lâm sàng bệnh lý của bệnh nhân ung thư vòm họng (NPC). Kết quả Phương pháp nhuộm miễn dịch kép đã được thực hiện trên 106 mẫu sinh thiết từ những bệnh nhân mới được chẩn đoán mắc NPC. Giá trị tiên lượng của mật độ tế bào lympho xâm nhập đã được đánh giá qua phân tích Kaplan-Meier và hồi quy Cox. Mật độ CD8+ TIL có tương quan tích cực với di căn hạch bạch huyết, trong khi mật độ Foxp3+ TIL có tương quan tiêu cực với giai đoạn T (P < 0.05). Đối với việc đánh giá sống sót, mật độ Foxp3+ TIL hoặc sự kết hợp giữa Foxp3+ TIL với GrB+ TIL đều có mối liên hệ với thời gian sống toàn bộ (OS) và thời gian sống không tiến triển (PFS) tốt hơn (P < 0.01) ở tất cả bệnh nhân và cả những bệnh nhân ở giai đoạn bệnh muộn (Giai đoạn III và IV, P < 0.01). Trong khi đó, mật độ thấp của CD8+TIL hoặc tỷ lệ cao của FOXP3+TIL so với CD8+TIL có liên quan đến PFS tốt hơn ở bệnh nhân giai đoạn đầu (Giai đoạn I và II, P < 0.05). Không có mối liên hệ đáng kể nào được tìm thấy giữa IL-17+ TIL với các đặc điểm lâm sàng bệnh lý hoặc khả năng sống sót của bệnh nhân NPC. Kết luận Nghiên cứu của chúng tôi xác định lần đầu tiên rằng tế bào lympho xâm nhập khối u Foxp3+ là yếu tố độc lập có lợi trong tiên lượng bệnh nhân NPC, đặc biệt đối với những bệnh nhân mắc bệnh ở giai đoạn muộn.

Từ khóa


Tài liệu tham khảo

Guigay J, Temam S, Bourhis J, Pignon JP, Armand JP: Nasopharyngeal carcinoma and therapeutic management: the place of chemotherapy. Ann Oncol. 2006, 17 (Suppl 10): x304-307. 10.1093/annonc/mdl278

Ma BB, Chan AT: Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer. 2005, 103: 22-31. 10.1002/cncr.20768

Sanguineti G, Bossi P, Pou A, Licitra L: Timing of chemoradiotherapy and patient selection for locally advanced nasopharyngeal carcinoma. Clin Oncol (R Coll Radiol). 2003, 15: 451-460.

Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, Valmori D: Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci USA. 2009, 106: 8635-8640. 10.1073/pnas.0900621106

Wei WI, Sham JS: Nasopharyngeal carcinoma. Lancet. 2005, 365: 2041-2054. 10.1016/S0140-6736(05)66698-6

Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004, 4: 757-768. 10.1038/nrc1452

Chan AT, Teo PM, Johnson PJ: Nasopharyngeal cancer. Cancer Treat Res. 2003, 114: 275-293.

Zeng YX, Jia WH: Familial nasopharyngeal carcinoma. Semin Cancer Biol. 2002, 12: 443-450. 10.1016/S1044579X02000871

Lakhdar M, Ben Aribia MH, Maalej M, Ladgham A: Selective homing of phenotypically lytic cells within nasopharyngeal carcinoma biopsies: numerous CD8- and CD16-positive cells in the tumor. Int J Cancer. 1991, 48: 57-61.

Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macri L, Daniele L, Oliaro A: Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg. 2009, 87: 365-371. discussion 371-362., 10.1016/j.athoracsur.2008.10.067

Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, Zee van der AG, Daemen T, Nijman HW: Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009, 58: 449-459. 10.1007/s00262-008-0583-5

Tomsova M, Melichar B, Sedlakova I, Steiner I: Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol. 2008, 108: 415-420. 10.1016/j.ygyno.2007.10.016

Dunn GP, Dunn IF, Curry WT: Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun. 2007, 7: 12-

Couzin J: Cancer. T cells a boon for colon cancer prognosis. Science. 2006, 313: 1868-1869. 10.1126/science.313.5795.1868b

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005, 102: 18538-18543. 10.1073/pnas.0509182102

Prall F, Duhrkop T, Weirich V, Ostwald C, Lenz P, Nizze H, Barten M: Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol. 2004, 35: 808-816. 10.1016/j.humpath.2004.01.022

Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S, Katoh H: CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004, 28: e26-31. 10.1097/00006676-200401000-00023

Sobhani I, Le Gouvello S: Critical role for CD8+FoxP3+ regulatory T cells in colon cancer immune response in humans. Gut. 2009, 58: 743-744. 10.1136/gut.2008.175521

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B: Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009, 27: 186-192. 10.1200/JCO.2008.18.7229

Gjerdrum LM, Woetmann A, Odum N, Burton CM, Rossen K, Skovgaard GL, Ryder LP, Ralfkiaer E: FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia. 2007, 21: 2512-2518. 10.1038/sj.leu.2404913

Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007, 132: 2328-2339. 10.1053/j.gastro.2007.03.102

Yu P, Fu YX: Tumor-infiltrating T lymphocytes: friends or foes?. Lab Invest. 2006, 86: 231-245. 10.1038/labinvest.3700389

Sasaki A, Tanaka F, Mimori K, Inoue H, Kai S, Shibata K, Ohta M, Kitano S, Mori M: Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol. 2008, 34: 173-179.

Yoshioka T, Miyamoto M, Cho Y, Ishikawa K, Tsuchikawa T, Kadoya M, Li L, Mishra R, Ichinokawa K, Shoji Y, Matsumura Y, Shichinohe T, Hirano S, Shinohara T, Itoh T, Kondo S: Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br J Cancer. 2008, 98: 1258-1263. 10.1038/sj.bjc.6604294

Lee NR, Song EK, Jang KY, Choi HN, Moon WS, Kwon K, Lee JH, Yim CY, Kwak JY: Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma. 2008, 49: 247-256. 10.1080/10428190701824536

Grabenbauer GG, Lahmer G, Distel L, Niedobitek G: Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res. 2006, 12: 3355-3360. 10.1158/1078-0432.CCR-05-2434

Gottschalk S, Bollard CM, Straathof KC, Louis CU, Savoldo B, Dotti G, Brenner MK, Heslop HE, Rooney CM: T cell therapies. Ernst Schering Found Symp Proc. 2006, 69-82.

Chan AT, Teo PM, Huang DP: Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol. 2004, 31: 794-801. 10.1053/j.seminoncol.2004.09.008

Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S: Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008, 93: 193-200. 10.3324/haematol.11702

Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, Montserrat E, Campo E, Banham AH: High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006, 108: 2957-2964. 10.1182/blood-2006-04-018218

Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C: The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005, 11: 8326-8331. 10.1158/1078-0432.CCR-05-1244

Bhairavabhotla RK, Verm V, Tongaonkar H, Shastri S, Dinshaw K, Chiplunkar S: Role of IL-10 in immune suppression in cervical cancer. Indian J Biochem Biophys. 2007, 44: 350-356.

Visser J, Nijman HW, Hoogenboom BN, Jager P, van Baarle D, Schuuring E, Abdulahad W, Miedema F, Zee van der AG, Daemen T: Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol. 2007, 150: 199-209.

Molling JW, de Gruijl TD, Glim J, Moreno M, Rozendaal L, Meijer CJ, Eertwegh van den AJ, Scheper RJ, von Blomberg ME, Bontkes HJ: CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer. 2007, 121: 1749-1755. 10.1002/ijc.22894

Lund JM, Hsing L, Pham TT, Rudensky AY: Coordination of early protective immunity to viral infection by regulatory T cells. Science. 2008, 320: 1220-1224. 10.1126/science.1155209

Dougan M, Dranoff G: Immune therapy for cancer. Annu Rev Immunol. 2009, 27: 83-117. 10.1146/annurev.immunol.021908.132544

Curotto de Lafaille MA, Lafaille JJ: Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?. Immunity. 2009, 30: 626-635. 10.1016/j.immuni.2009.05.002

van Maren WW, Jacobs JF, de Vries IJ, Nierkens S, Adema GJ: Toll-like receptor signalling on Tregs: to suppress or not to suppress?. Immunology. 2008, 124: 445-452. 10.1111/j.1365-2567.2008.02871.x

Moutsopoulos NM, Wen J, Wahl SM: TGF-beta and tumors--an ill-fated alliance. Curr Opin Immunol. 2008, 20: 234-240. 10.1016/j.coi.2008.04.003

Gallimore A, Godkin A: Regulatory T cells and tumour immunity - observations in mice and men. Immunology. 2008, 123: 157-163.

Barnett BG, Ruter J, Kryczek I, Brumlik MJ, Cheng PJ, Daniel BJ, Coukos G, Zou W, Curiel TJ: Regulatory T cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol. 2008, 622: 255-260.

Wang HY, Wang RF: Regulatory T cells and cancer. Curr Opin Immunol. 2007, 19: 217-223. 10.1016/j.coi.2007.02.004

Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA: Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol. 2009, 21: 281-285. 10.1016/j.coi.2009.05.007

Zhou L, Chong MM, Littman DR: Plasticity of CD4+ T cell lineage differentiation. Immunity. 2009, 30: 646-655. 10.1016/j.immuni.2009.05.001

Wang HY, Peng G, Guo Z, Shevach EM, Wang RF: Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol. 2005, 174: 2661-2670.

Li J, Zeng XH, Mo HY, Rolen U, Gao YF, Zhang XS, Chen QY, Zhang L, Zeng MS, Li MZ, Huang WL, Wang XN, Zeng YX, Masucci MG: Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One. 2007, 2: e1122- 10.1371/journal.pone.0001122

Oudejans JJ, Harijadi H, Kummer JA, Tan IB, Bloemena E, Middeldorp JM, Bladergroen B, Dukers DF, Vos W, Meijer CJ: High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent. J Pathol. 2002, 198: 468-475. 10.1002/path.1236

Yip WK, Abdullah MA, Yusoff SM, Seow HF: Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients. Clin Exp Immunol. 2009, 155: 412-422. 10.1111/j.1365-2249.2008.03793.x

Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ: Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007, 27: 635-646. 10.1016/j.immuni.2007.08.014

von Boehmer H: Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005, 6: 338-344. 10.1038/ni1180

Yang J, Chu Y, Yang X, Gao D, Zhu L, Wan L, Li M: Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009, 60: 1472-1483. 10.1002/art.24499

Mihara M, Ohsugi Y, Kishimoto T: Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody. Biofactors. 2009, 35: 47-51. 10.1002/biof.9

Bettelli E, Korn T, Kuchroo VK: Th17: the third member of the effector T cell trilogy. Curr Opin Immunol. 2007, 19: 652-657. 10.1016/j.coi.2007.07.020

Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM: Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006, 24: 677-688. 10.1016/j.immuni.2006.06.002

Voo KS, Wang YH, Santori FR, Boggiano C, Arima K, Bover L, Hanabuchi S, Khalili J, Marinova E, Zheng B, Littman DR, Liu YJ: Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA. 2009, 106: 4793-4798. 10.1073/pnas.0900408106

Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W: Phenotype, distribution, generation, functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009, 114 (6): 1141-9. 10.1182/blood-2009-03-208249

Chan AT, Felip E: Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008, 19 (Suppl 2): ii81-82. 10.1093/annonc/mdn098

Thông tin
Thông tin xuất bản

Molecular Cancer

Thông tin tác giả